ReviewBiomedical microdevices2026
Advances in microneedle Technology for Treatment of retinal degenerative diseases: a narrative review.
Review in Biomedical microdevices, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal degenerative diseases, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR), present significant therapeutic challenges due to the complex anatomical and physiological barriers of the posterior eye. Conventional drug delivery methods, particularly intravitreal injections, are often limited by their invasiveness, rapid drug clearance, and burden on patient compliance. Microneedle technology has emerged as a paradigm-modifying approach for ocular drug delivery, offering a minimally invasive platform to bypass barriers like the blood-retinal barrier while targeting specific ocular tissues. This narrative review provides a critical overview of the latest advancements in microneedle technology for treating retinal degeneration, evaluating diverse configurations-including solid, hollow, dissolvable, coated, and hydrogel-forming designs-and their efficacy in facilitating suprachoroidal, intravitreal, and subretinal administration. Recent clinical trials highlighted in this review demonstrate promising results regarding safety, delivery efficiency, and patient acceptability. However, the translation from bench to bedside still faces hurdles in scale-up production, regulatory standardization, and long-term stability assessment. We discuss these technological challenges and explore future developments, such as the integration of smart materials and personalized approaches, emphasizing the potential of microneedle systems to revolutionize treatment paradigms through precise, controlled delivery to the posterior eye segments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.